CP-615,003
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
N-(3-fluoro-4-(2-(propylamino)ethoxy)phenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide
|
|
| Identifiers | |
| CAS Number | 329016-45-7  |
| PubChem | CID 9820874 |
| ChemSpider | 7996623  |
| Chemical data | |
| Formula | C20H24FN3O3 |
| Molar mass | 373.421 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
CP-615,003 is a drug which acts as a subtype-selective partial agonist at GABAA receptors, and was developed by Pfizer as a potential anxiolytic; however, poor blood–brain barrier penetration make it primarily useful as a research ligand.[1][2]
References[edit]
- ^ Shaffer CL, Gunduz M, O'Connell TN, Obach RS, Yee S (November 2005). "Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolites". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33 (11): 1688–99. doi:10.1124/dmd.105.004630. PMID 16081672.
- ^ Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA (August 2007). "Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35 (8): 1341–9. doi:10.1124/dmd.106.013953. PMID 17470526.
